Oasmia Pharmaceutical AB (Sweden) announced that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea.
Technology and know-how are already transferred to Baxter and manufacturing is planned to commence within a short period of time. Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).
Apealea will be manufactured at Baxter’s manufacturing site in Halle/Westfalen (Germany), one of the most advanced facilities for cytotoxic contract manufacturing in the world. Manufacturing at Oasmia’s own site in Uppsala (Sweden) is now shifted to focus on the company’s other products, Doxophos and Docecal.
Oasmia Pharmaceutical AB (Uppsala, Sweden) develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications.
Baxter BioPharma Solutions (USA) operates as a full-service contract parenterals manufacturer. It offers frozen and aseptically filled flexible containers for pharma products; and clinical-scale and commercial-scale vial and syringe fillings for pharmaceutical customers. The company also offers manufacturing support services, which include formulation, quality control, analytical and microbiological services, and validation and regulatory assistance.